Work

A clinical retrospective study of anlotinib in combination with gemcitabine and albumin-bound paclitaxel for the first-line treatment of advanced pancreatic cancer

Year: 2025

Type: article

Abstract: Anlotinib has demonstrated efficacy and tolerability in treating various tumors. The purpose of this retrospective study is to assess the efficacy and safety of anlotinib combined with gemcitabine and albumin-bound paclitaxel as a first-line treatment for advanced pancreatic cancer. Patients with advanced pancreatic cancer who are not candidates for surgery were divided into two groups: anlotinib plus gemcitabine/nab-paclitaxel (A + AG) (n = 32) and gemcitabine/nab-paclitaxel alone (AG) (n = 39). Data was analyzed for clinical characteristics, survival benefits, and side effects. The median progression-free survival (mPFS) (7.4 m vs 5.1 m, p = 0.003) and the median overall survival (mOS) (15 m vs 9.6 m, p = 0.001) were both prolonged in the A + AG group compared to AG group. The objective response rate (ORR) (12.5% vs 5.1%, p = 0.399) and the disease control rate (DCR) (87.5% vs 74.4%, p = 0.233) only disclosed increasing trends in the A + AG group compared to the AG group. Univariate analysis identified that pathology type (p = 0.002) affects PFS, while pathology type (p = 0.003), and CA199 level (p = 0.020) affect OS in the AG groups. In the A + AG group, the Thymidine kinase (TR) level affected PFS (p = 0.014) and OS (p = 0.035). Multivariate analysis showed no clinical factors correlated with PFS and OS in both the A + AG and AG groups. The most common adverse effects were leukopenia (91.5%), fatigue/poor appetite (85.9%), nausea/vomiting (80.3%), and thrombocytopenia (77.5%). The incidence of grade III/IV adverse reactions was similar in both groups. No grade V adverse reactions occurred. This study demonstrates that anlotinib combined with the AG chemotherapy regimen provides a new first-line therapeutic choice for patients with advanced pancreatic cancer.

Source: Gastrointestinal Tumors

DOI: 10.48130/git-0025-0001

Authors: Yawen Zheng, Yuhan Zhou, Haiyan Xia, Wei Liang, Xiaowei Wei, Jin Zhou

Institutions: Nanjing First Hospital, Nanjing Medical University

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $990